HRSA Revises 340B Rebate Pilot Program, Alters Drug Pricing Compliance
HRSA revised its 340B Rebate Model Pilot to allow rebates instead of upfront discounts on select drugs.
Why it matters: Healthcare legal teams must adapt to new compliance rules and financial impacts from this pilot affecting drug pricing and hospital reimbursements. The program influences hospitals serving vulnerable populations and faces regulatory and congressional scrutiny.
- The revised pilot lets manufacturers meet 340B ceiling price obligations via rebates on certain drugs.
- It applies to drugs on the CMS Medicare Drug Price Negotiation Selected Drug Lists for 2026 and 2027.
- Manufacturers must submit applications by August 24, 2026, with approvals by September 24.
- The American Hospital Association warns the program imposes significant administrative and financial burdens on participating hospitals.
On July 31, 2026, the Health Resources and Services Administration (HRSA) announced a revised 340B Rebate Model Pilot Program that permits qualifying drug manufacturers to fulfill their 340B ceiling price obligations through post-sale rebates rather than upfront discounts. The 340B program requires drug manufacturers to provide outpatient drugs to eligible healthcare providers at reduced prices, ensuring affordable medications for underserved populations.
This updated pilot focuses on medications included in the CMS Medicare Drug Price Negotiation Selected Drug Lists for 2026 and 2027. These lists highlight drugs targeted for Medicare price negotiations aimed at lowering costs.
Manufacturers interested in participating must submit rebate model applications by August 24, 2026, with HRSA decisions on approval expected by September 24. Approved models will be implemented starting January 1, 2027, and require at least a one-year commitment.
The revision follows a federal court vacating the previous pilot in February 2026. After gathering input through a Request for Information closed in April 2026, HRSA revised the program to address legal and operational concerns.
The American Hospital Association (AHA) expressed significant concern regarding the complexity and cost of compliance under the new model. AHA President Rick Pollack said: "The AHA is deeply concerned that HHS has chosen to move forward with a 340B Rebate Model Program despite the overwhelming evidence that it will impose massive new administrative and financial burdens on hospitals that serve America’s most vulnerable patients." Hospitals fear increased tracking and reporting requirements linked to rebate administration.
This pilot will test how a rebate-based approach affects drug pricing compliance and 340B program integrity while aligning with ongoing Medicare drug price negotiations. Legal and regulatory teams should closely monitor how these changes influence reimbursement practices and potential congressional responses to drug pricing policies.
By the numbers:
- August 24, 2026 — deadline for manufacturers to apply for pilot participation
- September 24, 2026 — HRSA deadline for approving rebate models
- January 1, 2027 — revised 340B Rebate Model begins implementation
Yes, but: Though the AHA strongly opposes the pilot citing administrative burdens, HRSA maintains the rebate model could improve pricing transparency and program integrity. Legal teams should watch for further regulatory clarifications or legislative actions.
What's next: Congressional committees are expected to review the revised pilot and may conduct hearings addressing drug pricing impacts later in 2026.